



## Surgical Approach to Primary Lung Cancer and Metastatic Solid Tumors Involving the Lung

Guest Editors:

**Dr. Diego Luigi Cortinovis**

1. Medical Oncology Unit,  
Fondazione IRCCS San Gerardo  
dei Tintori, 20900 Monza, Italy  
2. Medicine and Surgery  
Department, University of Milano  
Bicocca, 20126 Milano, Italy

**Dr. Francesco Petrella**

Division of Thoracic Surgery,  
Fondazione IRCCS San Gerardo  
dei Tintori Monza, 20900 Monza,  
Italy

**Dr. Francesca Colonese**

Medical Oncology Unit,  
Fondazione IRCCS San Gerardo  
dei Tintori Hospital in Monza, Via  
Giambattista Pergolesi 33, 20900  
Monza, Italy

Deadline for manuscript  
submissions:  
**closed (15 September 2024)**



[mdpi.com/si/191595](https://mdpi.com/si/191595)

### Message from the Guest Editors

Dear Colleagues,

Lung cancer is the second most frequent tumor and the leading cause of cancer death among both women and men, causing almost 25% of all cancer deaths. On the other side, the lung is the second most frequent target of metastases that form solid tumors, and pulmonary metastasectomy represents the most common surgical procedure in thoracic surgery.

Lung metastasectomy is an effective therapeutic alternative in selected patients, depending on primary tumor's biology, disease-free interval, number and site of the nodule to be excised, planned extension of lung resection as well as available alternative therapeutic options. Another surgical option widely debated involves the field of synchronous or metachronous lung cancers paving the way to a personalized therapeutic strategy in particular in the era of immune-therapy and precision medicine.

In this Special Issue, we would like to analyze the most significant advancements in the therapy of both primary and secondary lung tumors.

We look forward to receiving your valuable participations.

Dr. Diego Luigi Cortinovis

Dr. Francesco Petrella

Dr. Francesca Colonese

*Guest Editors*

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

## Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, and **other databases**.

**Journal Rank:** JCR - Q2 (Oncology)

## Contact Us

Current Oncology Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/currentoncology](http://mdpi.com/journal/currentoncology)  
[currentoncology@mdpi.com](mailto:currentoncology@mdpi.com)  
[X@CurrentOncology](https://twitter.com/CurrentOncology)